GSK (LON:GSK) Posts Earnings Results

GSK (LON:GSK) announced its earnings results on Wednesday. The company reported GBX 54.60 EPS for the quarter, Digital Look Earnings reports. GSK had a return on equity of 28.35% and a net margin of 14.52%. The firm had revenue of GBX 888.70 billion during the quarter.

GSK Stock Down 3.7%

LON:GSK traded down GBX 71.50 during mid-day trading on Wednesday, hitting GBX 1,852. The stock had a trading volume of 52,256,086 shares, compared to its average volume of 12,516,905. The company has a market capitalization of £74.21 billion, a PE ratio of 15.72, a PEG ratio of 1.24 and a beta of 0.29. The stock has a 50-day simple moving average of GBX 1,850.33 and a two-hundred day simple moving average of GBX 1,949.81. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a twelve month low of GBX 1,664 and a twelve month high of GBX 2,282.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Specialty medicines supported growth. Third-quarter revenue reached approximately £8.9 billion, with new medicines and specialty drugs helping GSK slightly exceed expectations for core operating profit and core EPS. GSK tops third-quarter estimates as new medicines drive growth
• Positive Sentiment: Oncology pipeline expansion offers a longer-term catalyst. GSK plans to nearly double the number of cancer medicines in clinical trials next year, signaling increased investment in oncology and potential future growth. Separately, its rectal-cancer drug met its primary Phase 2 objective, while a partnered bone-cancer drug reportedly delayed disease progression in a late-stage China study. GSK to nearly double cancer drugs in trials
• Neutral Sentiment: 2026 guidance was reaffirmed. Management maintained its forecast for 3%–5% turnover growth and 7%–9% growth in core operating profit and core EPS. While this supports confidence in the plan, investors appeared disappointed that results did not prompt an upgrade. GSK keeps guidance as specialty drugs power sales
• Negative Sentiment: Vaccine weakness was the main pressure point. Vaccine revenue fell 2%, including a 5% decline for Shingrix and a 24% drop for Arexvy. The declines raised concerns about the durability of GSK’s vaccine franchise and overshadowed strength in specialty medicines. GSK Slides as Weak Vaccine Sales Overshadow Quarterly Beat
• Negative Sentiment: Reported profitability deteriorated. Reported operating profit fell 16% and total EPS declined 21%, partly because of a £328 million restructuring charge tied to the Accelerate Growth program. Higher financing costs also weighed on investor sentiment. GSK delivers Q3 earnings beat

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Berenberg Bank boosted their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Tuesday, October 20th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

Insiders Place Their Bets

In other GSK news, insider Anne Beal purchased 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Over the last three months, insiders purchased 2,151 shares of company stock valued at $6,021,921. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.